Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Segment Information (Tables)

v3.8.0.1
Note 11 - Segment Information (Tables)
6 Months Ended
Dec. 31, 2017
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
   
Quarter Ended
   
Six M
onths Ended
 
   
December 31,
   
December 31,
 
   
2017
   
2016
   
2017
   
2016
 
Net sales:
                               
Biotechnology
   
101,411
     
85,953
    $
196,487
    $
172,740
 
Protein Platforms
   
29,388
     
21,548
     
54,028
     
41,121
 
Diagnostics
   
23,429
     
24,330
     
48,415
     
48,563
 
Intersegment
   
(75
)
   
(24
)
   
(164
)
   
(36
)
Consolidated net sales
   
154,153
     
131,807
    $
298,766
    $
262,388
 
O
perating income:
                               
Biotechnology
  $
46,210
    $
39,474
    $
90,813
    $
81,594
 
Protein Platforms
   
6,119
     
1,843
     
9,175
     
2,052
 
Diagnostics
   
3,777
     
5,801
     
9,606
     
12,104
 
Segment
operating income
  $
56,106
    $
47,118
    $
109,594
    $
96,110
 
Costs recognized on sale of acquired inventory
   
(264
)
   
(789
)
   
(582
)
   
(2,133
)
Amortization of acquisition related intangible assets
   
(11,296
)
   
(11,627
)
   
(22,675
)
   
(21,815
)
Acquisition related expenses
   
(13,150
)
   
(12,056
)
   
(22,683
)
   
(15,588
)
Stock based compensation
   
(5,044
)
   
(4,055
)
   
(8,839
)
   
(7,245
)
Corporate general, selling, and administrative
expenses
   
(2,204
)
   
(710
)
   
(4,636
)
   
(2,293
)
Consolidated operating
income
   
24,148
     
17,881
    $
50,179
    $
47,036